Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
Marie-Léa GauciEmilie LanoyStéphane ChampiatCaroline CaramellaSamy AmmariSandrine AspeslaghAndrea VargaCapucine BaldiniRastilav BahledaAnas GazzahJean-Marie MichotSophie Postel-VinayEric AngevinVincent RibragAntoine HollebecqueJean-Charles SoriaCaroline RobertChristophe MassardAurélien MarabellePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
There are currently no differences in therapeutic strategies between CRs and PRs to anti-PD-(L)1. We found a striking difference in OS between these two types of responses. Our results are in favor of evaluating patient stratification strategies and intensification of treatments when tumor lesions of a partial responder to immunotherapy stop improving.See related commentary by Cohen and Flaherty, p. 910.